Saturday, March 2, 2024


Boehringer Ingelheim

Boehringer Ingelheim Collaborates with IBM to Revolutionize Antibody Discovery Using AI

Boehringer Ingelheim, a global pharmaceutical company, and IBM, a technology leader, have announced a groundbreaking collaboration aimed at transforming the discovery of novel therapeutic...

T3 Pharma’s Immuno-Oncology Platform Acquired by Boehringer Ingelheim

Boehringer Ingelheim has acquired T3 Pharma, a company that has developed a therapy platform using engineered Yersinia enterocolitica bacteria. These bacteria can deliver immune-modulating...

Boehringer Ingelheim Receives Approval for Ambitious Emission Reduction Targets from SBTi

Boehringer Ingelheim, a prominent biopharmaceutical company, has secured approval from the Science Based Targets initiative (SBTi) for its ambitious 2030 greenhouse gas (GHG) emission...

Latest news

Sticky Image